Treatment for Type-2-Diabetes News: Fixed Combination of DPP-4 and SGLT-2 Inhibitors

被引：0
|
作者：
不详
机构：
来源：
DIABETES STOFFWECHSEL UND HERZ | 2018年 / 27卷 / 03期
关键词：
TYPE-2; DIABETES-MELLITUS; MILLION PEOPLE; SITAGLIPTIN; THERAPY; RISK;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：157 / 158
页数：2
相关论文
共 50 条
  • [31] SGLT-2 inhibitors and their potential in the treatment of diabetes
    Rosenwasser, Rebecca F.
    Sultan, Senan
    Sutton, David
    Choksi, Rushab
    Epstein, Benjamin J.
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2013, 6 : 453 - 467
  • [32] Cost-Effectiveness of DPP-4 Inhibitor and SGLT2 Inhibitor Combination Therapy for Type 2 Diabetes
    Pawaskar, Manjiri
    Bilir, S. Pinar
    Kowal, Stacey
    Gonzalez, Claudio
    Rajpathak, Swapnil
    Davies, Glenn
    AMERICAN JOURNAL OF MANAGED CARE, 2019, 25 (05): : 231 - +
  • [33] Cardiovascular Effects of New Oral Glucose-Lowering Agents DPP-4 and SGLT-2 Inhibitors
    Scheen, Andre J.
    CIRCULATION RESEARCH, 2018, 122 (10) : 1439 - 1459
  • [34] Effect of SGLT-2 Inhibitors Versus DPP-4 Inhibitors on Peripheral Artery Disease Risk Among People With Type 2 Diabetes: A 48-Month Prospective Study
    Giugliano, Dario
    Longo, Mirian
    Caruso, Paola
    Gicchino, Maurizio
    Scappaticcio, Lorenzo
    Bellastella, Giuseppe
    Esposito, Katherine
    Maiorino, Maria Ida
    DIABETES OBESITY & METABOLISM, 2025,
  • [35] Risk of hyperkalaemia in patients with type 2 diabetes mellitus prescribed with SGLT2 versus DPP-4 inhibitors
    Wu, Mei-zhen
    Teng, Tiew-Hwa Katherine
    Tsang, Christopher Tze-Wei
    Chan, Yap-Hang
    Lee, Chi-Ho
    Ren, Qing-wen
    Huang, Jia-Yi
    Cheang, Iok-fai
    Tse, Yi-Kei
    Li, Xin-li
    Xu, Xin
    Tse, Hung-Fat
    Lam, Carolyn S. P.
    Yiu, Kai-Hang
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2024, 10 (01) : 45 - 52
  • [36] Comparison of SGLT2 inhibitors versus DPP-4 inhibitors as combination with metformin in patients with acute myocardial infarction with diabetes
    Lyu, Y.
    Oh, S.
    Kim, J.
    Jeong, M.
    Kim, S.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S474 - S475
  • [37] Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus
    Giorgio Sesti
    Angelo Avogaro
    Sara Belcastro
    Benedetta Maria Bonora
    Marina Croci
    Giuseppe Daniele
    Marco Dauriz
    Francesco Dotta
    Caterina Formichi
    Simona Frontoni
    Cecilia Invitti
    Emanuela Orsi
    Fabiana Picconi
    Veronica Resi
    Enzo Bonora
    Francesco Purrello
    Acta Diabetologica, 2019, 56 : 605 - 617
  • [38] Efficacy and Safety of Triple Therapy with SGLT-2 Inhibitor, DPP-4 Inhibitor, and Metformin in Type 2 Diabetes: A Meta-Analysis
    Li, Mengdi
    Wang, Sining
    Wang, Xiaoli
    ALTERNATIVE THERAPIES IN HEALTH AND MEDICINE, 2023, 29 (05) : 320 - 326
  • [39] THE COMPARISON OF SGLT2 INHIBITORS AND DPP-4 INHIBITORS ON HEALTH CARE EXPENDITURE AND UTILIZATION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
    Wagner, T.
    Dixon, D. L.
    Salgado, T. M.
    VALUE IN HEALTH, 2020, 23 : S117 - S117
  • [40] DPP-4 inhibitors for the treatment of type 2 diabetes: a methodology overview of systematic reviews
    Juan Ling
    Long Ge
    Ding-hua Zhang
    Yong-feng Wang
    Zhuo-lin Xie
    Jin-hui Tian
    Xiao-hui Xiao
    Ke-hu Yang
    Acta Diabetologica, 2019, 56 : 7 - 27
12345